Loading
Control (Standard treatment) / Osteoarthritis (OA) of the Knee / Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Phase EARLY_PHASE1 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered early-phase interventional trial examining GLP-1 receptor agonists for weight loss optimization prior to total knee replacement in obese patients with osteoarthritis. No results are yet reported in this registry record; the study addresses a gap identified by the sponsors in the literature, as no RCTs of this intervention currently exist.
Early Phase 1, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Osteoarthritis (OA) of the Knee; age from 40 Years; to 80 Years. Intervention: GLP-1RA. Compared with: Control (standard treatment) — Placebo Comparator. n = 54. 1 site: Hong Kong.
Study registration identifies a gap: no prior RCTs examine GLP-1RAs for weight loss before TKR Primary outcomes are visual analogue scale pain and analgesic consumption assessed at enrolment, 1 month, preoperatively, and at 6 weeks, 3 months, 6 months, and 12 months post-surgery Rationale cites retrospective evidence that weight loss interventions can improve post-TKR physical function
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This trial addresses an evidence gap identified by the authors: no prior RCTs have examined GLP-1 receptor agonists for preoperative weight loss optimization in TKR patients. Results, when available, may inform perioperative management of obese surgical candidates, though the small planned sample and early phase suggest results will be preliminary and require confirmation.
This is a study registration for an early-phase interventional trial that is actively recruiting; no results are reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This trial addresses an evidence gap identified by the authors: no prior RCTs have examined GLP-1 receptor agonists for preoperative weight loss optimization in TKR patients. Results, when available, may inform perioperative management of obese surgical candidates, though the small planned sample and early phase suggest results will be preliminary and require confirmation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Registry record from ClinicalTrials.gov (NCT06807970). This is a study registration, not published results. Lead sponsor: The University of Hong Kong. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: EARLY_PHASE1. Study type: INTERVENTIONAL. Enrollment: 54 participants (ESTIMATED). Conditions: Osteoarthritis (OA) of the Knee. Interventions: DRUG: Glucagon-like peptide-1 receptor agonists (GLP 1 RA); OTHER: Control (Standard treatment). Primary outcome measures: Visual analogue scale and analgesic consumption , As part of the standard of care when undergoing TKR, patients are routinely assessed at enrolment, 1 month and same day before surgery, and at 6 weeks,3 months, 6 months and 12 months post-surgery.. Brief summary: Studies have shown that obese patients undergoing total knee replacement (TKR) surgery face a higher risk of perioperative issues such as increased use of pain medication, surgical site infections, and the need for revision surgeries compared to non-obese patients. Obesity is also linked to more significant preoperative pain and lingering symptoms post-surgery. Consequently, there's a growing interest in weight loss interventions prior to TKR to enhance perioperative care and outcomes. Recent retrospective studies have indicated that such interventions can improve physical function post-TKR. Research focusing on weight loss interventions before joint replacement surgery is limited. There is currently a gap in research regarding RCTs on weight loss interventions using anti-obesity drugs before TKR, particularly in Asian populations. One promising avenue under exploration involves the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) as anti-obesity medication before total knee replacement (TKR) surgery. However, there are currently no randomized controlled trials (RCTs) examining the effects of GLP-1RAs on knee arthroplasty outcomes. Large database studies have indicated that GLP-1RAs may decrease the likelihood of certain post-surgery complications but increase the risk of others. In summary, addressing obesity through weight loss interventions, particularly with GLP-1RAs, holds promise for improving outcomes in TKR patients. However, further research, including randomized controlled trials, is necessary to fully understand the effects of GLP-1RAs on perioperative outcomes and patient health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.